This Week’s Top 5 Infectious Disease Stories
So far, these are Contagion's 5 most-read stories of 2023.
FDA Accepts BLA for Nirsevimab for RSV Prevention for Infants
Developed by Sanofi and AstraZeneca, the single-dose long-acting antibody was designed to help protect all infants from birth through their first respiratory syncytial virus (RSV) season.
Vaxcyte’s Pneumococcal Vaccine Receives FDA Breakthrough Therapy Designation
The 24-valent investigational pneumococcal conjugate vaccine, VAX-24, met its primary endpoints in a phase 1/2 trial.
In the Aftermath of the Pandemic, IDSA Looks to Address COVID-19's Health Care Disparities
A new Infectious Diseases Society of America (IDSA) board member and vice president offers some insights on the leadership’s goals and direction for 2023.
FDA Accepts BLA for Pfizer Meningococcal Vaccine
The company’s vaccine candidate, MenABCWY, which is indicated for adolescents was given a Prescription Drug User Fee Act (PDUFA) goal date for later this year.
What We Know About XBB.1.5, the New and Highly Contagious Omicron Subvariant
In just a month, the XBB.1.5 variant went from causing 1% to over 40% of new COVID-19 infections.
Cyproheptadine Arm of COVID-19 Treatment Study Terminated
Due to negative results, the I-SPY COVID Trial is no longer evaluating cyproheptadine to treat critically ill COVID-19 patients.
Shifting to Shorter Courses of Antibiotic Therapy for Common Pediatric Infections
In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.
Working Toward Eliminating Hepatitis
Health programs and efforts to inform the public about the importance of sharing liver education can play a major role in prevention as well as patient care.
How the COVID-19 Pandemic Changed State-Level Cigarette Sales
During the COVID-19 pandemic, cigarette sales differed from projected sales volume. One study examined these trends at the state level.
STIs: Neglected During COVID-19
Sexually transmitted infections (STIs) received little attention during the pandemic, but the truth is the STIs did not stop infection increases shortly after the quarantine.
Medical Masks Or N95s For COVID-19 Protection in Health Care?
Although medical masks were noninferior to N95 in a multinational study of frontline health care workers, variability in circumstances between countries prevented researchers from drawing firm conclusions.
A Rare Case of Positive Heterophile Antibody in a Patient With West Nile Virus
This unusual Case Study describes a young woman who presented with an acute onset of headaches and dizziness and was found to have aseptic meningitis.
The Top 5 Video Interviews of 2022
A look back on some of the significant discussions with clinicians, researchers, and infectious disease stakeholders.
Employee Health After the COVID-19 Pandemic: Stronger Than Yesterday
For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.
Updates and Controversies in Necrotizing Soft Tissue Infections
Changes in microbiology and antimicrobial resistance patterns warrant reevaluation of our current therapies for this condition.
Preparing for the Next Long-acting Antiretrovirals
Clinicians can make room for infrequent treatment options as patients enjoy their daily lives.
The Year's Top COVID-19 Stories
New booster shots, antigen testing, and a shrinking incubation period: these were the top COVID-19 stories of 2022.
Why Aren’t We Better Protecting Our Youngest Children Against Infections?
Vaccinations and mitigations for COVID-19 and other respiratory viruses have not been made a priority for young children. Let’s change this before the next big surge hits.
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
In Case You Missed It: The Week's Top Infectious Disease Stories
A new monoclonal antibody, invasive group A strep, and genital herpes topped the list of this week's most-read stories.
SHEA: Do Not Screen Symptom-Free Patients for COVID-19 Upon Hospital Admission
The new recommendation from the organization believes it will help avoid delays in patient care.
Would You Try Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bacteremia?
This study was one of the largest to address the use of IV ceftriaxone in the context of MSSA bacteremia compared with cefazolin.
Determining Long Term Immunity May Aid in Understanding Vaccine Efficacy
Virax Biolabs has developed a T-cell testing platform to develop an immune risk profile against viral threats.
FDA Approves Lenacapavir for HIV Treatment
This therapy is the first of a new class of antiretrovirals, and it is indicated for people with multi-drug resistance, intolerance, or safety considerations.
Antimicrobial Prescribing in the Telehealth Setting: Framework for Stewardship During a Period of Rapid Acceleration Within Primary Care
Telemedicine use is likely to continue expanding even as the COVID-19 pandemic slowly resolves.
FDA Approves Monoclonal for COVID-19 Treatment in Hospitalized Adults
Roche’s Actemra is the first FDA approved monoclonal antibody to be used for COVID-19.
FDA Announces Next VRBPAC Looking at Future of COVID-19 Vaccine Regimens
The committee will meet on January 26 to discuss whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified.
Flu and RSV and Amoxicillin? Oh My!
Editor-in-Chief Jason Gallagher discusses the surging number of cases of influenza and RSV while there is a concomitant shortage of amoxicillin suspension.
NP and PA Network Opens its HIV Center of Excellence
A central portal to support clinical practice for patients with or at risk for HIV was launched.
